Scholarlink

Background <p>Ranitidine, a histamine-2 (H2) receptor antagonist, is widely used for acid-peptic disorders. Although generally safe, it is a rare but recognized cause of drug-induced anaphylaxis, with an estimated incidence of 0.2–0.7% for H2 receptor blockers and proton pump inhibitors. We report a near-fatal case of ranitidine-induced anaphylactic shock successfully managed in a rural hospital.</p> Case presentation <p>A 35-year-old female developed sudden shortness of breath, hypotension, and drowsiness within minutes of receiving a 50 mg intravenous (IV) dose of ranitidine for epigastric discomfort at a local clinic. She had no prior exposure to ranitidine or known allergies. On arrival, her blood pressure was 60 mmHg systolic, pulse 130/min, and SpO₂ 60%. She had diffused urticaria and wheezing. A diagnosis of anaphylactic shock was made. Immediate management included high-flow oxygen, intramuscular epinephrine (0.5 mg, 1:1000), followed by intravenous hydrocortisone. Significant improvement occurred within 10 minutes and she was discharged after 24 hours of observation.</p> Conclusion <p>This case highlights that ranitidine, although commonly used, can rarely trigger severe anaphylactic shock even in patients without prior exposure or known allergies. Early recognition of the reaction and timely administration of intramuscular epinephrine were key to the patient’s rapid recovery. Awareness of this potential adverse reaction is important for all clinicians who administer H2-receptor antagonists.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Anaphylactic shock following intravenous ranitidine in rural Nepal: a case report

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年12月16日

查看全文
  • Rojee Shrestha,
  • Ashal Timalsina,
  • Arjun Gaire,
  • Roshan Acharya,
  • Anupa Subedi,
  • Aayusha Suwal

摘要

Background

Ranitidine, a histamine-2 (H2) receptor antagonist, is widely used for acid-peptic disorders. Although generally safe, it is a rare but recognized cause of drug-induced anaphylaxis, with an estimated incidence of 0.2–0.7% for H2 receptor blockers and proton pump inhibitors. We report a near-fatal case of ranitidine-induced anaphylactic shock successfully managed in a rural hospital.

Case presentation

A 35-year-old female developed sudden shortness of breath, hypotension, and drowsiness within minutes of receiving a 50 mg intravenous (IV) dose of ranitidine for epigastric discomfort at a local clinic. She had no prior exposure to ranitidine or known allergies. On arrival, her blood pressure was 60 mmHg systolic, pulse 130/min, and SpO₂ 60%. She had diffused urticaria and wheezing. A diagnosis of anaphylactic shock was made. Immediate management included high-flow oxygen, intramuscular epinephrine (0.5 mg, 1:1000), followed by intravenous hydrocortisone. Significant improvement occurred within 10 minutes and she was discharged after 24 hours of observation.

Conclusion

This case highlights that ranitidine, although commonly used, can rarely trigger severe anaphylactic shock even in patients without prior exposure or known allergies. Early recognition of the reaction and timely administration of intramuscular epinephrine were key to the patient’s rapid recovery. Awareness of this potential adverse reaction is important for all clinicians who administer H2-receptor antagonists.